Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Associated Therapies: -

Clinical Trials

Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation

Phase 4

Terminated

Conditions: Coronary Artery Disease

Interventions: Drug: Aspirin plus clopidogrel
Drug: Clopidogrel

First Posted Date: 2015-07-10

Last Posted Date: 2017-02-23

Lead Sponsor: CHEOL WHAN LEE, M.D., Ph.D

Target Recruit Count: 364

Registration Number: NCT02494284

Locations: 🇰🇷
Cheju Halla General Hospital, Cheju, Korea, Republic of
🇰🇷
Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
🇰🇷
Eulji University Hospital, Daejeon, Korea, Republic of

and more 9 locations

Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)

Phase 4

Completed

Conditions: Aortic Stenosis
Inflammation
Thrombosis

Interventions: Drug: Clopidogrel
Drug: Ticagrelor

First Posted Date: 2015-07-01

Last Posted Date: 2022-07-20

Lead Sponsor: University Hospitals Cleveland Medical Center

Target Recruit Count: 60

Registration Number: NCT02486367

Locations: 🇺🇸
UH Cleveland Medical Center, Cleveland, Ohio, United States

Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone PCI

Phase 4

Completed

Conditions: Endothelial Dysfunction
Coronary Artery Disease
Myocardial Ischemia

Interventions: Drug: Clopidogrel
Drug: Ticagrelor

First Posted Date: 2015-06-11

Last Posted Date: 2016-03-11

Lead Sponsor: University Hospital of Limerick

Target Recruit Count: 61

Registration Number: NCT02469740

Locations: 🇮🇪
University Hospital Limerick, Dooradoyle, Limerick, Ireland

Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM)

Phase 4

Conditions: Coronary Artery Disease
Diabetes Mellitus. Type 2

Interventions: Drug: Ticagrelor
Drug: Clopidogrel

First Posted Date: 2015-05-29

Last Posted Date: 2016-04-14

Lead Sponsor: Spanish Society of Cardiology

Target Recruit Count: 30

Registration Number: NCT02457130

Locations: 🇪🇸
Hospital Clínico San Carlos, Madrid, Spain
🇪🇸
Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
🇪🇸
Hospital Universitari de Bellvitge - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain